Novo Nordisk semaglutide data shows new health benefits across chronic diseases

Novo Nordisk (NVO) “announced that new data spanning the company’s industry-leading portfolio across metabolic and cardiovascular health will be presented at the upcoming 32nd European Congress on Obesity, 11-14 May 2025. The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT, as well as part 1 of the phase 3 ESSENCE trial in metabolic dysfunction-associated steatohepatitis . Data will also be presented on the wider societal impacts of treating and preventing obesity, alongside analysis of the burden of obesity in adolescents. “Obesity is one of the greatest healthcare challenges we face globally, impacting the lives of hundreds of millions of people. Without effective interventions, the global burden of obesity and its complications will continue to rise,” said Stephen Gough, senior vice president and head of Chief Medical Office at Novo Nordisk. “Our broad and robust semaglutide data presented at ECO, including its impact on weight loss in a real-world setting and its early clinical effect on cardiovascular events and death, significantly adds to the growing body of evidence showing the value of semaglutide to individuals, healthcare systems and society.”